Head-to-head · WeighScore
eMed vs Spry
The verdict
eMed takes it — 57.4/100 to 56.8/100, but only just.
eMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. eMed is a digital health platform best known for at-home diagnostics that now runs a clinician-supported GLP-1 weight management program. Spry is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | eMed | Spry |
|---|---|---|
| WeighScore | 57.4/100 | 56.8/100 |
| Grade | C | C |
| Scorecard rank | #398 | #408 |
| Semaglutide | Not disclosed | $199/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $299/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #398 · C
Strengths
- Prescribes FDA-approved branded GLP-1s (semaglutide and tirzepatide)
- At-home blood collection makes lab work convenient
- Clinician review and ongoing side-effect plus adherence support
- Works with CVS Caremark so eligible employees can buy through benefits
- Established digital health company with national scale
Where it loses points
- Distributed mainly via employers, with limited direct cash-pay access
- No public transparent monthly price for individuals
- Eligibility and subsidy depend on what the employer chooses to cover
- Best suited to workforces, not casual self-pay shoppers
Graded #408 · C
Strengths
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
Where it loses points
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.